The principal documentary evidence obtained by the Commission consists of:
statement of Rhône-Poulenc of 19 May 1999 plus annexes ("Rhône-Poulenc statement"),
supplemental statement of Rhône-Poulenc of 25 May 1999 plus annexes ("Rhône-Poulenc supplemental statement"),
statement of Roche of 2 June 1999 ("Hoffmann-La Roche statement"),
statement of BASF of 15 June 1999 ("BASF statement"),
statement of Solvay Pharmaceuticals BV (concerning vitamin D3) of 29 June 1999 ("first Solvay statement"),
documentation provided by Roche by letter of 22 June 1999 (bundle A),
documentation provided by BASF by letter of 23 June 1999 (bundle B),
reply of Roche concerning vitamin E under Article 11 dated 9 July 1999, plus annexes 1 to 14 (bundle C),
statement of Daiichi of 9 July 1999 (Daiichi Statement) concerning vitamin B5 plus documentary evidence (bundle D),
reply of Roche (vitamins A, E, B2, B5, C, etc) under Article 11 of 16 July 1999, plus annexes,
reply of BASF (vitamins A, E, B5, C) under Article 11 of 16 July 1999 plus tables,
letter of Roche of 30 July 1999 concerning vitamins B1, B6, D3, ciotin and carotinoids plus annexes,
statement of Solvay Pharmaceuticals BV of 14 September 1999 plus appendices ("second Solvay Statement"),
documentation supplied by Takeda on 7 September 1999 concerning arrangements in B1, B2, B6, C and folic acid (bundle E),
documentation supplied by Takeda on 18 October 1999 concerning arrangements in folic acid (bundle F),
reply of Takeda of 18 and 20 October 1999 to request for information concerning vitamins B1 and B6,
statement of Eisai of 12 October 1999 plus annexed documents (Eisai statement),
reply of Tanabe dated 11 October 1999 to request for information concerning biotin plus appendices,
reply of Merck dated 26 October 1999 to request for information concerning biotin,
letter of Merck dated 22 November 1999 to request for information concerning vitamins B1 and B6,
reply of Takeda dated 10 January 2000 to request for information concerning folic acid.